Teza Capital Management LLC Decreases Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Teza Capital Management LLC lessened its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 92.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 364 shares of the company's stock after selling 4,676 shares during the quarter. Teza Capital Management LLC's holdings in Eli Lilly and Company were worth $281,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. True Wealth Design LLC raised its position in shares of Eli Lilly and Company by 12.9% during the 4th quarter. True Wealth Design LLC now owns 131 shares of the company's stock worth $101,000 after acquiring an additional 15 shares in the last quarter. State of Wyoming increased its stake in Eli Lilly and Company by 92.8% in the fourth quarter. State of Wyoming now owns 1,552 shares of the company's stock valued at $1,198,000 after purchasing an additional 747 shares during the last quarter. Stonebrook Private Inc. raised its holdings in Eli Lilly and Company by 2.0% during the fourth quarter. Stonebrook Private Inc. now owns 2,864 shares of the company's stock worth $2,211,000 after purchasing an additional 56 shares in the last quarter. Strategic Wealth Partners Ltd. raised its holdings in Eli Lilly and Company by 19.8% during the fourth quarter. Strategic Wealth Partners Ltd. now owns 14,301 shares of the company's stock worth $11,040,000 after purchasing an additional 2,359 shares in the last quarter. Finally, Strive Asset Management LLC purchased a new stake in shares of Eli Lilly and Company during the 4th quarter worth approximately $462,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on LLY. HSBC cut shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and lowered their target price for the company from $1,150.00 to $700.00 in a report on Monday, April 28th. Morgan Stanley reaffirmed an "overweight" rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Cantor Fitzgerald initiated coverage on Eli Lilly and Company in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $975.00 target price on the stock. Hsbc Global Res cut Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research report on Monday, April 28th. Finally, StockNews.com upgraded Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and eighteen have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $1,011.37.

Insider Buying and Selling at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the company's stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the transaction, the chief accounting officer now directly owns 5,840 shares of the company's stock, valued at $4,778,521.60. This represents a 14.62% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Stock Down 1.2%

LLY stock opened at $745.72 on Wednesday. The stock has a market capitalization of $706.75 billion, a PE ratio of 63.68, a price-to-earnings-growth ratio of 1.40 and a beta of 0.48. The company has a fifty day moving average of $795.44 and a 200-day moving average of $804.82. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. Eli Lilly and Company has a one year low of $677.09 and a one year high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The business had revenue of $12.73 billion during the quarter, compared to analysts' expectations of $12.77 billion. During the same period in the prior year, the firm posted $2.58 EPS. Eli Lilly and Company's revenue for the quarter was up 45.2% compared to the same quarter last year. As a group, analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th will be given a $1.50 dividend. This represents a $6.00 annualized dividend and a yield of 0.80%. The ex-dividend date is Friday, May 16th. Eli Lilly and Company's payout ratio is 48.82%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.